Document:

Exhibit 4.2

  

   

    

  

    AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

    

    

    THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 1st day of June, 2020,
      by and among Cue Health Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.

    

    

    RECITALS

    

    

    WHEREAS, certain Investors (the “Prior Investors”) own outstanding shares of the Company’s Series A Preferred Stock and Series B Preferred Stock, and are parties to the Amended and Restated Investors’ Rights Agreement, dated as of December 20,
        2017 (the “Prior Agreement”), and it is a condition to closing of the sale of the Series C Preferred Stock under the Purchase Agreement that, pursuant to the requirements of Section 6.6 of the Prior
        Agreement, the requisite parties to the Prior Agreement amend and restate the Prior Agreement by entering into this Agreement;

    

    

    WHEREAS, the Company and certain Investors are
        parties to that certain Series C Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”); and

    

    

    WHEREAS, the undersigned Prior Investors, as
        holders of a majority of the outstanding Registrable Securities, the Company and the Series C Investors, desire to enter into this Agreement to amend, restate and replace their rights and obligations under the Prior Agreement with the rights and
        obligations set forth in this Agreement.

    

    

    NOW, THEREFORE, the parties hereby agree as
        follows:

    

    

    1          Definitions.  For purposes of this Agreement:

    

    

    “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
      controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
      general partners or managing members of, or shares the same management company with, such Person.  For purposes of this Agreement, Cove, and any future company under common administration with Cove, shall be considered “Affiliates”.

    

    

    “Common Stock” means shares of the Company’s Common Stock, par value $0.00001 per share.

    

    

    “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
      company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the quantification and/or detection of molecular analytes, but shall not include (i) any financial investment firm or collective investment
      vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding voting power of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the Board of Directors of any
      Competitor, (ii) JJDC, (iii) Decheng, (iv) Section 32, (v) Madrone, (vi) Acme, or NVGA I, LLC.

    
      
        

    

    
    

    

    “Cove” means, collectively, Cove Investors I, LLC, a Delaware limited liability company, and Cove Investors II,
      LLC, a Delaware limited liability company.

    

    

    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject
      under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon:  (i) any untrue statement or alleged untrue statement of a
      material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
      material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange
      Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

    

    

    “Decheng” means Decheng Capital China Life Sciences USD Fund III, L.P. a Cayman Islands exempted limited
      partnership.

    

    

    “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in
      each case, directly or indirectly), Common Stock, including options and warrants.

    

    

    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
      thereunder.

    

    

    “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or
      a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to
      be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being
      registered.

    

    

    “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration
      form under the Securities Act subsequently adopted by the SEC.

    

    

    “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under
      the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

    

    

    “GAAP” means generally accepted accounting principles in the United States.

    
      2

      
        

    

    

    

    “Holder” means any holder of Registrable Securities who is a party to this Agreement.

    

    

    “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, registered
      domestic partner, sibling, mother-in-law, father-in- law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein.

    

    

    “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
      Agreement.

    

    

    “IPO” means the Company’s first firm commitment underwritten public offering of its Common Stock under the
      Securities Act.

    

    

    “JJDC” means Johnson & Johnson Innovation – JJDC, Inc.

    

    

    “Madrone” means Madrone Opportunity Fund, L.P., a Delaware limited partnership.

    

    

    “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
      5,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof); provided, however, that for purposes of this Agreement, (i) JJDC
      shall be deemed a Major Investor for so long as JJDC holds at least 697,107 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof),
      (ii) PGVC 2018 LLC (“PGVC”) shall be deemed a Major Investor for so long as PGVC holds at least 697,107 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other
      recapitalization or reclassification effected after the date hereof), and (iii) Section 32 shall be deemed a Major Investor for so long as Section 32 holds at least 697,107 shares of Registrable Securities (as adjusted for any stock split, stock
      dividend, combination, or other recapitalization or reclassification effected after the date hereof).

    

    

    “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as
      well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.

    

    

    “Person” means any individual, corporation, partnership, trust, limited liability company, association or other
      entity.

    

    

    “Preferred Directors” means any director of the Company that the holders of record of the Series A Preferred Stock,
      Series B Preferred Stock or Series C Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation, as amended.

    

    

    “Preferred Stock” means shares of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C
      Preferred Stock.

    

    

    
      3

      
        

    

    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
      (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or
      issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) and (ii)
      above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2
      any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.

    

    

    “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
      outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.

    

    

    “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection

        2.12(b) hereof.

    

    

    “Section 32” means Section 32 Fund 2, LP.

    

    

    “SEC” means the Securities and Exchange Commission.

    

    

    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

    

    

    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

    

    

    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
      thereunder.

    

    

    “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
      the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.

    

    

    “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.00001 per share.

    

    

    “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.00001 per share.

    

    

    “Series C Preferred Stock” means shares of the Company’s Series C-1 Preferred Stock and Series C-2 Preferred Stock.

    

    

    “Series C-1 Preferred Stock” means shares of the Company’s Series C-1 Preferred Stock, par value $0.00001 per
      share.

    

    

    “Series C-2 Preferred Stock” means shares of the Company’s Series C-2 Preferred Stock, par value $0.00001 per
      share.

    

    

    
      4

      
        

    

    2          Registration Rights.  The Company covenants and agrees as
        follows:

    

    

    2.1          Demand Registration.

    

    

    (a)          Form S-1 Demand.  If at any time
        after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the
        Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to the Registrable Securities then outstanding with an anticipated aggregate offering price of at least $20 million, then the Company shall
        within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within
        sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any
        additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case,
        subject to the limitations of Subsections 2.1(c) and 2.3.

    

    

    (b)          Form S-3 Demand.  If at any time when
        it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with
        respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the Company shall (i) within ten (10) days after the date such request is given,
        give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration
        statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the
        Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.

    

    

    (c)          Notwithstanding the foregoing obligations,
        if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would
        be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such
        action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business
        purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time
        periods with respect to filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given;
        provided, however, that the Company may not invoke this right more than twice in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or the account
        of any other stockholder during such one hundred twenty (120) day period other than an Excluded Registration.

    

    

    
      5

      
        

    

    (d)          The Company shall not be obligated to
        effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)(i) during the period that is ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one
        hundred eighty (180) days after the effective date of, a Company- initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
        effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
        pursuant to a request made pursuant to Subsection 2.1(b).  The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is ninety
        (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in
        good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately
        preceding the date of such request.  A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the
        Initiating Holders withdraw their request for such registration (other than as a result of a material adverse change to the Company, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement
        pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d).

    

    

    2.2          Company Registration.  If the Company proposes to
        register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other
        than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.  Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall,
        subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration.  The Company shall have the right to terminate or withdraw any
        registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration.  The expenses (other than Selling Expenses)
        of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6.

    

    

    
      6

      
        

    

    2.3          Underwriting Requirements.

    

    

    (a)          If, pursuant to Subsection 2.1, the
        Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall
        include such information in the Demand Notice.  The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders.  In such event, the right of any Holder to include such
        Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.  All
        Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such
        underwriting.  Notwithstanding any other provision of this Subsection 2.3, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then
        the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such
        Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such
        selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the
        underwriting.

    

    

    (b)          In connection with any offering involving an
        underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the
        underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company.  If the total number of
        securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is
        compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
        determine will not jeopardize the success of the offering.  If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are
        included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all
        such selling Holders.  Notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely
        excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the
        selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering.  For purposes of the provision in this Subsection 2.3(b) concerning
        apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family
        Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling
        Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

    

    

    
      7

      
        

    

    2.4          Obligations of the Company.  Whenever required under
        this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

    

    

    (a)          prepare and file with the SEC a registration
        statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered
        thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that
        such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in
        such registration;

    

    

    (b)          prepare and file with the SEC such
        amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by
        such registration statement;

    

    

    (c)          furnish to the selling Holders such numbers
        of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

    

    

    
      8

      
        

    

    (d)          use its commercially reasonable efforts to
        register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be
        required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

    

    

    (e)          in the event of any underwritten public
        offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

    

    

    (f)          use its commercially reasonable efforts to
        cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company
        are then listed;

    

    

    (g)          provide a transfer agent and registrar for
        all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

    

    

    (h)          promptly make available for inspection by
        the selling Holders, any managing underwriter participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
        and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter,
        attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

    

    

    (i)          notify each selling Holder, promptly after
        the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

    

    

    (j)          after such registration statement becomes
        effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.

    

    

    In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the
      Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

    

    

    
      9

      
        

    

    2.5          Furnish Information.  It shall be a condition precedent
        to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
        Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

    

    

    2.6          Expenses of Registration.  All expenses (other than
        Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for
        the Company; and the reasonable fees and disbursements of one counsel for the selling Holders not to exceed Twenty Five Thousand Dollars ($25,000) (“Selling Holder Counsel”), shall be borne and paid by the
        Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request
        of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn
        registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be.  All Selling Expenses relating to
        Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

    

    

    2.7          Delay of Registration.  No Holder shall have any right
        to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

    

    

    2.8          Indemnification.          If any Registrable Securities
        are included in a registration statement under this Section 2:

    

    

    (a)          To the extent permitted by law, the Company
        will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for
        each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or
        other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
        that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
        unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any
        such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.

    

    

    
      10

      
        

    

    (b)          To the extent permitted by law, each selling
        Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
        Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
        Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
        expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
        any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement
        of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any
        Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful
        misconduct by such Holder.

    

    

    (c)          Promptly after receipt by an indemnified
        party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to
        be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof.  The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying
        party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified
        party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of
        such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action.  The
        failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that
        such failure materially prejudices the indemnifying party’s ability to defend such action.  The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under
        this Subsection 2.8.

    

    

    
      11

      
        

    

    (d)          To provide for just and equitable
        contribution to joint liability under the Securities Act in any case in which either:  (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially
        determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
        the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8,
        then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative
        fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable
        considerations.  The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
        omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission;
        provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration
        statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further
        that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such
        Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

    

    

    (e)          Unless otherwise superseded by an
        underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a
        registration under this Section 2, and otherwise shall survive the termination of this Agreement.

    

    

    2.9          Reports Under Exchange Act.  With a view to making
        available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3,
        the Company shall:

    

    

    (a)          make and keep available adequate current
        public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;

    

    

    (b)          use commercially reasonable efforts to file
        with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

    

    

    
      12

      
        

    

    (c)          furnish to any Holder, so long as the Holder
        owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date
        of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may
        be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities
        without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

    

    

    2.10          Limitations on Subsequent Registration Rights.  From
        and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any
        securities of the Company that would provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had
        the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in
        accordance with Subsection 6.9.

    

    

    2.11          “Market Stand-off” Agreement.  Each Holder hereby
        agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company on its own behalf of shares of its Common Stock or
        any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other
        period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the
        restrictions contained in applicable FINRA rules, or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any
        option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such
        shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
        securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.  The foregoing provisions of this Subsection 2.11 shall apply only to
        the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or purchased at or after the IPO, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the
        immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value,
        and shall be applicable to the Holders only if all officers and directors are subject to the same restriction and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one
        percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock).  The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection

          2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.  Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection
        with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto.  Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the
        underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements.

    

    

    
      13

      
        

    

    2.12          Restrictions on Transfer.

    

    

    (a)          The Preferred Stock and the Registrable
        Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
        specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act.  A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable
        Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.

    

    

    (b)          Each certificate, instrument, or book entry
        representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
        consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form:

    

    

    THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.  SUCH SHARES MAY NOT BE
      SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

    

    

    THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF
      WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

    

    

    
      14

      
        

    

    The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted
      Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12.

    

    

    (c)          The holder of such Restricted Securities, by
        acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2.  Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under
        the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer.  Each such notice shall describe the manner and circumstances of the
        proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be
        reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed
        sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to
        the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge,
        or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company.  The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144;
        or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. 

        Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection

          2.12(b), except that such certificate instrument or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with
        any provisions of the Securities Act.

    

    

    2.13          Termination of Registration Rights.  The right of any
        Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earlier to occur of:

    

    

    (a)          the closing of a Liquidation Event, as such
        term is defined in the Company’s Certificate of Incorporation;

    

    

    
      15

      
        

    

    (b)          such time after the IPO that Rule 144 or
        another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three (3) month period without registration; and

    

    

    (c)          the fifth anniversary of the IPO.

    

    

    3          Information and Observer Rights.

    

    

    3.1          Delivery of Financial Statements.  The Company shall
        deliver to each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company:

    

    

    (a)          as soon as practicable, but in any event
        within one hundred twenty (120) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year; and (iii) a statement of stockholders’ equity as of
        the end of such year, all such financial statements audited and certified by independent public accountants selected by the Company; provided, however, that the
        audit requirement shall not be required until the Company’s Board of Directors determines that it is appropriate.

    

    

    (b)          as soon as practicable, but in any event
        within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of
        stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be
        required in accordance with GAAP);

    

    

    (c)          as soon as practicable, but in any event
        within thirty (30) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial
        statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP);

    

    

    (d)          as soon as practicable, but in any event
        within forty-five (45) days after the end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital
        stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number
        of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company;

    

    

    (e)          within thirty (30) days prior to the
        beginning of each new fiscal year, a budget and business plan for such fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets,
        income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company.

    

    

    
      16

      
        

    

    If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
      statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

    

    

    Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection

        3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such
      registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause
      such registration statement to become effective.

    

    

    3.2          Inspection.  The Company shall permit each Major
        Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and
        records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be
        obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in
        form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

    

    

    3.3          Observer Rights.

    

    

    (a)          Observer Rights.  So long as Sherpa
        Ventures Fund, LP (“Acme”) owns not less than 1,090,180 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected
        after the date hereof), the Company shall invite one (1) representative of Acme to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes,
        consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided
        further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client
        privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.

    

    

    
      17

      
        

    

    (b)          Observer Rights.  So long as Cove
        Investors I, LLC and Cove Investors II, LLC (collectively, “Cove”) collectively owns not less than 1,090,180 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or
        other recapitalization or reclassification effected after the date hereof), the Company shall invite one (1) representative of Cove to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give
        such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
        respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such
        meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.

    

    

    (c)          Observer Rights.          So long as
        JJDC owns not less than 697,107 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), the Company shall invite one (1)
        representative of JJDC to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
        directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold
        any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in
        disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.

    

    

    (d)          Observer Rights.  So long as Decheng
        owns not less than 819,247 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), the Company shall invite one (1)
        representative of Decheng to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
        directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold
        any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in
        disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.

    

    

    
      18

      
        

    

    3.4          Termination of Information and Observation Rights.  The
        covenants set forth in Subsections 3.1, 3.2 and 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of an IPO that results in the conversion of all outstanding Preferred Stock to
        Common Stock, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Liquidation Event, as such term is defined in the Company’s Certificate of
        Incorporation, whichever event occurs first.

    

    

    3.5          Confidentiality.  Each Investor agrees that such
        Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
        notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor),
        (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of
        confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
        obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser is not a Competitor of the Company (as reasonably
        determined by the Company’s Board of Directors), and agrees to be bound by the provisions of this Subsection 3.5; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of
        business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that
        the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.  Rights to Future Stock Issuances.

    

    

    4          Rights to Future Stock Issuances.

    

    

    4.1          Right of First Offer.  Subject to the terms and
        conditions of this Subsection 4.1, and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor.  A Major Investor shall be entitled to
        apportion the right of first offer hereby granted to it in such proportions as it deems appropriate among itself and its Affiliates; provided that each such Affiliate (x) is not a Competitor of the Company (as reasonably determined by the Company’s
        Board of Directors), unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and the Voting Agreement of even date herewith among the Company, the Investors and
        the other parties named therein, as an “Investor” under each such agreement (provided that any Competitor (as reasonably determined by the Company’s Board of Directors) shall not be entitled to any rights as a Major Investor under Subsections
          3.1, 3.2, 3.3 and 4.1 hereof).

    

    

    
      19

      
        

    

    (a)          The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it
        proposes to offer such New Securities.

    

    

    (b)          By notification to the Company within twenty
        (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the
        Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held by such
        Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities).  At the expiration of such twenty (20) day period,
        the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do
        likewise.  During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up
        to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or
        indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon
        conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares.  The closing of any sale pursuant to this Subsection

          4.1(b) shall occur within the later of one hundred twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).

    

    

    (c)          If all New Securities referred to in the
        Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and
        sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice.  If the Company does not enter into an
        agreement for the sale of the New Securities within such period, or if such agreement is not consummated within forty-five (45) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall
        not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1.

    

    

    (d)          The right of first offer in this Subsection

          4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) equity securities issued in the IPO; and (iii) the issuance of shares of Series B Preferred Stock to Additional Purchasers
        pursuant to Subsection 1.3 of the Purchase Agreement.

    

    

    
      20

      
        

    

    4.2          Termination.  The covenants set forth in Subsection
          4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO that results in the conversion of all outstanding Preferred Stock to Common Stock, (ii) when the Company first becomes subject to the
        periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first.

    

    

    5          Additional Covenants.

    

    

    5.1          Insurance.  The Company will use commercially reasonable
        efforts to cause its existing Directors and Officers liability insurance coverage in an amount not less than $5,000,000 to be maintained until such time as the Board of Directors, including a majority of the Preferred Directors, determines that
        such insurance should be discontinued.

    

    

    5.2          Employee Agreements.  The Company will cause each person
        now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary
        rights assignment agreement.

    

    

    5.3          Employee Stock.  Unless otherwise approved by the Board
        of Directors, including a majority of the Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be
        required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
        employment or service, and the remaining shares vesting in equal quarterly installments over the following thirty-six (36) months, (ii) a market standoff provision substantially similar to that in Subsection 2.11, and (iii) no acceleration
        of vesting upon a Liquidation Event, as defined in the Company’s Certificate of Incorporation, as amended from time to time.  In addition, unless otherwise approved by the Board of Directors, including a majority of the Preferred Directors, the
        Company shall retain a “right of first refusal” on employee transfers until the IPO and shall have the right to repurchase unvested shares at the lower of cost or fair market value upon termination (with or without cause) of employment of a holder
        of restricted stock.

    

    

    5.4          Matters Requiring Investor Director Approval.  So long
        as the holders of Preferred Stock are entitled to elect Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the
        affirmative vote of a majority of the Preferred Directors:

    

    

    (a)          incur any expenditures, or create or
        authorize aggregate indebtedness, in either case in excess of $500,000 that is not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business;

    

    

    
      21

      
        

    

    (b)          increase the number of shares of Common
        Stock reserved for issuance under the Company’s 2014 Equity Incentive Plan or create any new equity incentive plan;

    

    

    (c)          create any committee of the Board of
        Directors;

    

    

    (d)          acquire more than fifty percent (50%) of the
        voting securities, or all or substantially all of the assets of any business (whether by stock or asset purchase, merger, consolidation or otherwise) for consideration in excess of $500,000;

    

    

    (e)          establish or invest in any subsidiary or
        joint venture;

    

    

    (f)          enter into any materially new line of
        business or materially alter or change the Company’s business as it is presently conducted and contemplated to be conducted today;

    

    

    (g)          terminate or change the Company’s then
        current chief executive officer;

    

    

    (h)          transfer of any intellectual property or
        grant any exclusive rights to the Company’s intellectual property or any exclusive distribution rights;

    

    

    (i)          effect any sales or other dispositions of
        Company assets outside the ordinary course of business exceeding $250,000; or

    

    

    (j)          enter into any agreement or transaction with
        any officer or director or employee or stockholder of the Corporation or any family member thereof.

    

    

    5.5          Board Matters.  Unless otherwise determined by the vote
        of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule.  The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred
        (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors.  The Company shall enter in an indemnification agreement with each current and future Preferred Director in a form approved by the Board
        of Directors, including at least two of the Preferred Directors.  Additionally, the Preferred Director designated by JJDC shall be entitled in such person’s discretion to be a member of any committee of the Board of Directors.

    

    

    5.6          Successor Indemnification.  If the Company or any of its
        successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
        successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws,
        the Certificate of Incorporation (as amended, or elsewhere, as the case may be.

    

    

    
      22

      
        

    

    5.7          Right to Conduct Activities.  The Company hereby agrees
        and acknowledges that Acme, Decheng, Madrone, Section 32 and JJDC (together with their respective Affiliates) are investment funds or venture arms of their Affiliates, and as such make or hold investments in, or trade in securities of, companies
        that may be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted).  The Company hereby agrees that, to the extent permitted under applicable law, Acme, Decheng, Madrone, Section 32 and JJDC
        (together with their respective Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by Acme, Decheng, Madrone, Section 32 or JJDC in any entity competitive with the Company, or activities
        of such Affiliates that may be competitive to the Company, or (ii) actions taken by any partner, officer or other representative of Acme, Decheng, Madrone, Section 32 or JJDC, to assist any such competitive company (including, but not limited to,
        JJDC’s activities in connection with its Affiliates), whether or not such action was taken as a member of the board of directors of such company or otherwise, and whether or not such action has a detrimental effect on the Company; provided,
        however, that the foregoing shall not relieve (x) any of the Investors from liability associated with unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the
        Company from any liability associated with his or her fiduciary duties to the Company.  The Company acknowledges that Decheng, Acme, Section 32, Madrone and JJDC are in the business of private equity investing and therefore review the business
        plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company.  Nothing in this Agreement shall preclude, create an obligation
        or duty, or in any way restrict Decheng, Madrone, Section 32, Acme and JJDC (or any of their respective Affiliates) from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or
        participating in any particular enterprise, whether or not such enterprise has products or services which compete with those of the Company.

    

    

    5.8          Founder Grants.  Promptly after the Closing, the
        Company’s Board of Directors will approve new equity grants to each of the Company’s Founders, Ayub Khattak and Clint Sever, equal to six percent (6%) in the aggregate (four percent (4%) to Ayub Khattak and two percent (2%) to Clint Sever) of the
        Company’s fully diluted capitalization immediately after the Closing, subject to 4 year vesting (no cliff), and on the same terms and conditions as earlier grants to such Founders.

    

    

    5.9          Termination of Covenants.  The covenants set forth in
        this Section 5 (other than Sections 5.6, 5.7 and 5.10) shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO that results in the conversion of all outstanding
        Preferred Stock to Common Stock, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, and (iii) upon a Liquidation Event, as such term is defined in the Company’s
        Certificate of Incorporation.

    

    

    5.10          Indemnification Matters.  The Company hereby
        acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses
        and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”).  The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund
        Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or
        on behalf of any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights
        such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery
        of any kind in respect thereof.  The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the
        Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company.

    

    

    
      23

      
        

    

    6          Miscellaneous.

    

    

    6.1          Successors and Assigns.  The rights under this Agreement
        may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder, (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one
        or more of such Holder’s Immediate Family Members, or (iii) after such transfer holds at least five percent (5%) shares of Registrable Securities (subject to appropriate adjustment for stock, splits, stock dividends, combinations, and other
        recapitalizations; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to
        which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. 
        For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a
        trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually
        for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement.  The terms and conditions of this Agreement inure to the benefit of and are
        binding upon the respective successors and permitted assignees of the parties.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees
        any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.

    

    

    6.2          Governing Law.  This Agreement shall be governed by the
        internal law of the State of Delaware, without giving effect to any conflict of law principles that would result in the application of any law other than the law of the State of Delaware.

    

    

    
      24

      
        

    

    6.3          Counterparts.  This Agreement may be executed in two (2)
        or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
        complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
        and effective for all purposes.

    

    

    6.4          Titles and Subtitles.  The titles and subtitles used in
        this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.

    

    

    6.5          Notices.  All notices and other communications given or
        made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
        recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
        (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.  All communications shall be sent to the respective
        parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or
        address as subsequently modified by written notice given in accordance with this Subsection 6.5.  If notice is given to the Company, a copy shall also be sent to Wilmer Hale LLP, 950 Page Mill Road, Palo Alto, CA 94304, Attn:  E. Thom
        Rumberger Jr., Esq.

    

    

    6.6          Amendments and Waivers.  Any term of this Agreement may
        be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders
        of a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c); and provided further that any provision hereof may be waived
        by any waiving party on such party’s own behalf, without the consent of any other party and that Subsection 3.3(a) may not be amended without the written consent of Acme, Subsection 3.3(b) may not be amended without the written
        consent of Cove and Subsection 3.3(c) may not be amended without the written consent of JJDC.  Notwithstanding the foregoing, any amendment to this Agreement that would change the definition of “Major Investor” to increase the Registrable
        Security ownership threshold for such status shall not apply to a then-current Major Investor without the written consent of such Major Investor (and absent such consent, notwithstanding any amendment to this Agreement to the contrary, such Major
        Investor shall remain a “Major Investor” following such amendment).  Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the
        written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be
        deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) Subsections

          3.1 and 3.2, Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written
        consent of the holders of a majority of the Registrable Securities then outstanding and held by the Major Investors.  Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any
        Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other
        parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9.  The Company shall give prompt notice of any amendment, modification or termination hereof or waiver
        hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver.  Any amendment, modification, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on
        all parties hereto, regardless of whether any such party has consented thereto.  No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or
        continuing waiver of any such term, condition, or provision.

    

    

    
      25

      
        

    

    6.7          Severability.  In case any one or more of the provisions
        contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
        unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.

    

    

    6.8          Aggregation of Stock.  All shares of Registrable
        Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they
        deem appropriate.

    

    

    6.9          Additional Investors.  Notwithstanding anything to the
        contrary contained herein, if the Company issues additional shares of the Company’s Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock shall become a party
        to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder.  No action or consent by the Investors shall be required for such
        joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.

    

    

    6.10          Entire Agreement.  Upon the effectiveness of this
        Agreement, the Prior Agreement shall be deemed amended and restated to read in its entirety as set forth in this Agreement.  This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement
        among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

    

    

    
      26

      
        

    

    6.11          Waiver of Right of First Offer.  Except as set forth in
        the proviso below, solely for purposes of the transactions contemplated by the Purchase Agreement and solely with respect to the issuance of up to 27,308,229 shares of Series C-1 Preferred Stock and 1,690,380 shares of Series C-2 Preferred Stock,
        the right of first offer set forth in Section 4 of the Prior Agreement is hereby waived in its entirety; provided, however, that the foregoing waiver shall have no force or effect with respect to, and
        nothing contained herein shall (or shall be deemed to) waive or modify the rights, preferences, privileges, or remedies of, any Major Investor who exercised or exercises its right of first offer in respect of the Company’s offering of Series C
        Preferred Stock, in each case, in accordance with Section 4 of the Prior Agreement.

    

    

    6.12          Dispute Resolution.  The parties (a) hereby irrevocably
        and unconditionally submit to the jurisdiction of the state courts of the State of California and to the jurisdiction of the United States District Court for the Southern District of California for the purpose of any suit, action or other
        proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of State of California or the United States District Court
        for the Southern District of California, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the
        above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or
        the subject matter hereof may not be enforced in or by such court.

    

    

    In any dispute between the parties, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief
      to which such party may be entitled.  Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the Southern District of California or any court of the State of California
      having subject matter jurisdiction.

    

    

    6.13          Delays or Omissions.  No delay or omission to exercise
        any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be
        construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
        or thereafter occurring.  All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

    

    

    
      27

      
        

    

    6.14          Press Releases.  The Company hereby agrees not to issue
        any press releases or make any public communications in connection with any Investor’s purchase of shares of Series C Preferred Stock pursuant to the Purchase Agreement without the prior written consent of Acme, Decheng and JJDC, except as may be
        required by law.  The expenses of any press releases or public communication issued by the Company in accordance with this Subsection 6.14 shall be borne by the Company.

    

    

    [Remainder of Page Intentionally Left Blank]

    

    

    
      28

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	COMPANY:
	
             

          	
             

          	
             

          
	
             

          	CUE HEALTH INC.
	
             

          	
             

          	
             

          
	
             

          	By: 

            	/s/ Ayub Khattak

          
	
             

          	Name:	Ayub Khattak
	
             

          	Title:	President and Chief Executive Officer
	
             

          	
             

          	
             

          
	 	Address:	
            4980 Carroll Canyon Rd Suite 100,  

            San Diego, CA 92121

          

                

    
    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    

    

    
      	
               

            	INVESTORS:
	
               

            	
               

            	
               

            
	
               

            	
              SHERPA VENTURES FUND, LP

            
	
               

            	
               

            	
               

            
	
               

            	By: 

            	Sherpa Ventures Fund GP, LLC
	
               

            	Its:	General Partner
	
               

            	
               

            	
               

            
	 	By: 

              	/s/ Scott Stanford 

            
	 	Name:	 Scott Stanford
	 	Title:	Managing Partner
	
               

            	
               

            	
               

            
	 	Address:	800 Market Street, Floor 8

              San Francisco, CA 94102

              portfolio@sherpa.com

    

       

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    
      
        	
                 

              	INVESTORS:
	
                 

              	
                 

              	
                 

              
	
                 

              	
                SHERPA VENTURES FUND, LP

              
	
                 

              	
                 

              	
                 

              
	
                 

              	By: 

              	Sherpa Ventures Fund GP, LLC
	
                 

              	Its:	General Partner
	
                 

              	
                 

              	
                 

              
	
                 

              	By: 

                	/s/ Scott Stanford

              
	 	Name: 

                	 Scott A. Stanford
	 	Title:  	Managing Director
	 	 	 
	 	Address:	800 Market Street, Floor 8

                San Francisco, CA 94102

                portfolio@sherpa.com

      

              

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    
      	
               

            	INVESTORS:
	
               

            	
               

            	
               

            
	
               

            	JOHNSON & JOHNSON INNOVATION – JJDC, INC.
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Asish K. Xavier. Ph.D.

              
	
               

            	Name: 

              	Asish K. Xavier. Ph.D.
	 	Title:	Vice President, Venture Investments
	
               

            	
               

            	
               

            
	
               

            	Address:	
              410 George Street

                New Brunswick, New Jersey 08901

                Attention:  Vijay Murthy & Linda Vogel

            
	 	 	 
	 	 	 
	 	 	 
	 	 	 

    

                

    
    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	INVESTORS:
	
             

          	
             

          	
             

          
	
             

          	
            BROAD STREET PRINCIPAL INVESTMENTS, L.L.C. 

            

          
	
             

          	
             

          	
             

          
	
             

          	By:	/s/ Tammy A. Keely

          
	
             

          	Name:	 Tammy A. Keely
	
             

          	Title:	Vice President
	
             

          	
             

          	
             

          

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	INVESTORS:
	
             

          	
             

          	
             

          
	
             

          	10100 LLC
	
             

          	
             

          	
             

          
	
             

          	By: 

            	 /s/ Tara Dhingra   

            

          
	
             

          	Name: 

            	 Tara Dhingra
	
             

          	Title:	President
	
             

          	
             

          	
             

          
	
             

          	
            Dept #1178

            PO Box 2652

            Menlo Park, CA

          
	
             

          	
             

          	
             

          

      

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          	
             

          
	
             

          	COVE INVESTORS I, LLC

          
	
             

          	
             

          	
             

          
	
             

          	By: 

          	Oakmont Corporation
	
             

          	Its:  	Administrator
	
             

          	
             

          	
             

          
	
             

          	By: 

            	/s/ Peter Carlton  

          
	
             

          	Name:	Peter Carlton
	
             

          	Title:  	President
	 	Address:	865 South Figueroa St, 7th Floor

            Los Angeles, CA 90017

      

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          	
             

          
	
             

          	TARSADIA FOUNDATION
	
             

          	
             

          	
             

          
	
             

          	By: 

            	/s/ Maya Patel  

          
	
             

          	Name: 

            	Maya Patel
	
             

          	Title:	 President
	
             

          	
             

          	
             

          
	
             

          	Address:	520 Newport Center Drive, 21st Floor

            Newport Beach, CA 92660
	
             

          	
             

          	
             

          

                

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    

    

    
      	
               

            	INVESTORS:	
               

            
	
               

            	
               

            	
               

            
	
               

            	
              FORESITE CAPITAL FUND IV, L.P.

            
	
               

            	
               

            	
               

            
	
               

            	By: 

            	Foresite Capital Management IV, LLC
	
               

            	Its:	 General Partner
	
               

            	
               

            	
               

            
	
               

            	By: 

              	/s/ Dennis D. Ryan 

            
	
               

            	Name: 

              	 Dennis D. Ryan
	
               

            	Title:	
              Chief Financial Officer

            
	 	 	 
	 	
              Address:

              

            	
              600 Montgomery Street, Suite 4500

               San Francisco, CA 94111 

            

    

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    

    

    
      
        	
                 

              	INVESTORS:
	
                 

              	
                 

              	
                 

              
	
                 

              	
                FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

              
	
                 

              	
                 

              	
                 

              
	
                 

              	By:	Foresite Capital Opportunity Management V, LLC
	
                 

              	Its:	 General Partner
	
                 

              	
                 

              	
                 

              
	
                 

              	By:	/s/ Dennis D. Ryan  

              
	
                 

              	Name: 

                	 Dennis D. Ryan
	
                 

              	Title: 

                	Chief Financial Officer
	 	 	 
	 	Address:	
                600 Montgomery Street, Suite 4500

                 San Francisco, CA 94111 

              

      

    

     

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	 	INVESTORS:
	 	 
	
             

          	
            LINDAMERE DRIVE, LLC

          
	 	 
	 	By:

          	Oakmont Corporation
	
             

          	
            Its:  

          	
            Administrator

          
	 	 	 
	
             

          	
            By: 

              

          	
            /s/ Peter Carlton

            

          
	
             

          	
            Name:

          	
            Peter Carlton

               

          
	
             

          	
            Title:

          	
             

          
	 	 	 
	 	Address:	865 South Figueroa St, 7th

            Floor Los Angeles, CA 90017

     

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    

    	 	INVESTORS:
	 	 
	
             

          	
            COVE INVESTORS II, LLC

          
	 	 
	 	By:

          	Oakmont Corporation
	
             

          	
            Its:  

          	
            Administrator

          
	 	 	 
	
             

          	
            By: 

              

          	
            /s/ Peter Carlton

            

          
	
             

          	
            Name:

          	
            Peter Carlton

               

          
	
             

          	
            Title:

          	
            President

          
	 	 	 
	 	Address:	865 South Figueroa St, 7th

            Floor Los Angeles, CA 90017

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    

    	 	INVESTORS:
	 	 
	
             

          	
            GREYSCALE, LLC

          
	 	 
	 	By:

          	/s/ Matt Agnune          

            
	
             

          	
            Name:

            

          	
            Matt Agnune

          
	 	Title:

          	CFO

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            AMERICAN FIDELITY CORPORATION

          
	
             

          	
             

          
	
             

          	
            By:

          	
            John Cassil

          
	
             

          	
            Its: 

          	
            SVP, CFO

          
	
             

          	
             

          	
             

          
	
             

          	
            By:

          	/s/ John Cassil     

          
	
             

          	
            Name:

          	John Cassil
	
             

          	
            Title:

          	SVP, CFO
	
             

          	
             

          	
             

          
	
             

          	
            Address:

          	9000 Cameron Parkway

            Oklahoma City, OK 73114

            Attn:  Jim Wheeler

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            FLAT WORLD (CUE) LP

          
	
             

          	
             

          
	
             

          	
            By:

          	 /s/ Anna-Marie Wascher    

          
	
             

          	
            Name:

          	Anna-Marie Wascher
	
             

          	
            Title:

          	Managing Partner

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            FLAT WORLD (CUE) LP

          
	
             

          	
             

          
	
             

          	
            By:

          	 /s/ Anna-Marie Wascher    

          
	
             

          	
            Name:

          	Anna-Marie Wascher
	
             

          	
            Title:

          	Chief Executive Officer

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	ROHAN OZA
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Rohan Oza    

          
	 	 	 
	
             

          	Address:

          	145 Reade Street Apt. 175

            New York, NY 10013

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    
      	
               

            	
              INVESTORS:

            
	
               

            	
               

            
	
               

            	PGVC 2018 LLC
	
               

            	
               

            
	
               

            	
              By:

            	Jabodon PT Company dba Pritzker Group
	
               

            	
              Its: 

            	 Managing Member
	
               

            	
               

            	
               

            
	
               

            	
              By:

            	/s/ Christopher E. Girgenti     

              
	
               

            	
              Name:

            	Christopher E. Girgenti
	
               

            	
              Title:

            	Authorized Signatory

    

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            ANP HANOVER HOLDINGS LLC

          
	
             

          	
             

          
	
             

          	
            By:

          	 Jabodon PT Company, Manager
	
             

          	
             

          	
             

          
	
             

          	
            By:

          	/s/ Eric A. Schreiner       

            
	
             

          	
            Name:

          	Eric A. Schreiner
	
             

          	
            Title:

          	
            President

          
	
             

          	
             

          	
             

          
	
             

          	
            Address:

          	
            111 S. Wacker Drive, Suite 4000

              Chicago, IL 60606

              Email:  investments@pritzkergroup.com

          

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	RONO, LLC
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Rohan Oza      

          
	
             

          	
            Name:

          	Rohan Oza
	
             

          	
            Title:

          	Manager
	 	 	 
	 	Address:	145 Reade Street Apt. 175

            New York, NY 10013

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

    
       

      

      	
               

            	
              INVESTORS:

            
	
               

            	
               

            
	
               

            	Hlth Wrk LLC
	
               

            	
               

            
	
               

            	
              By:

            	/s/ Chris Achar 

            
	 	 	 
	 	Address:	6443 Lindenhurst Avenue

              Los Angeles, CA 90048

      

      

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	SECTION 32 FUND 2, LP
	
             

          	
             

          
	
             

          	
            By:

          	
            Section 32 GP 2, LLC,

          
	
             

          	
            Its: 

          	General Partner
	
             

          	
             

          	
             

          
	
             

          	
            By:

          	
            /s/ Jennifer L. Kercher       

            

          
	
             

          	
            Name:

          	Jennifer L. Kercher
	
             

          	
            Title:

          	Chief Operating Officer
	
             

          	
             

          	
             

          
	
             

          	
            Address:

          	
            171 Main Street, #671

              Los Altos, CA 94022

          
	 	 	 
	 	Email:

          	 notice@section32.com
	 	Attn: 

          	 Chief Operating Officer

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	DECHENG CAPITAL CHINA LIFE

            SCIENCES USD FUND Ill, L.P.
	
             

          	
             

          
	
             

          	
            By:

          	
             Decheng Capital Management III

            (Cayman), LLC 

          
	
             

          	
            Name:

            

          	Xiangmin Cui Title:  Managing Director
	
             

          	
             

          	
             

          
	
             

          	
            By:

          	
            /s/ Xiangmin Cui     

          
	
             

          	
            Name:

          	Xiangmin Cui
	
             

          	
            Title:

          	Managing Director
	
             

          	
             

          	
             

          
	
             

          	
            Address:

          	
            3000 Sand Hill Road

              Building 2, Suite 110

              Menlo Park, CA 94025

          
	 	 	 
	 	Attn:

          	 
	 	Fax:	 
	 	Email:

          	

          
	 	Email: 

          	[***]

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            WEIJI CUI AND JIN ZHOU, TRUSTEES OF 

            THE CUI FAMILY REVOCABLE TRUST

          
	
             

          	
             

          
	
             

          	
            By:

          	
            /s/ Weiji Cui        

            

          
	
             

          	
            Name:

          	Weiji Cui
	
             

          	
            Title:

          	
            Trustee

          

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	
            MADRONE OPPORTUNITY FUND, L.P.

            by its General Partner:

          
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Greg Penner   

          
	
             

          	
            Name:

          	Greg Penner
	
             

          	
            Title:

          	Managing Member
	 	 	 
	 	Address:

          	1149 Chestnut Street, Suite 200

            Menlo Park, CA 94025

            madrone@weimail.com

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	RCHI, LLC
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Daniel Larsen    
	
             

          	
            Name:

          	Daniel Larsen
	
             

          	
            Title:

          	Assistant Vice President & Secretary
	 	 	 
	 	Address:

          	
            4980 Carroll Canyon Rd Suite 100, 

            San Diego, CA 92121

          

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	RAJENDRA SINGH2008 FAMILY TRUST
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Neera Singh        
	
             

          	
            Name:

          	Neera Singh
	
             

          	
            Title:

          	Trustee
	 	 	 
	 	Address:

          	23 Indian Creek Island Road

            Indian Creek Village, FL 33154

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	NEERAJ CHANDRA
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Neeraj Chandra   

          
	
             

          	
            Name:

          	Neeraj Chandra

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	NVGA I, LLC
	
             

          	
             

          
	
             

          	
            By:

          	TFC Manager, LLC
	
             

          	
            Its: 

          	Manager
	
             

          	
             

          	
             

          
	
             

          	
            By:

          	/s/ Vikram Patel          

            
	
             

          	
            Name:

          	Vikram Patel
	
             

          	
            Title:

          	Manager
	
             

          	
             

          	
             

          
	
             

          	
            Address:

          	
            4980 Carroll Canyon Rd Suite 100, 

            San Diego, CA 92121

          

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	ART99 INVESTMENTS LLC
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Wendi Murdoch       
	
             

          	
            Name:

          	Wendi Murdoch
	
             

          	
            Title:

          	Managing Member
	 	 	 
	 	Address:

          	c/o NKSFB

            810 Seventh Ave, Suite 1701

            New York, NY 10019

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	SOFREH CAPITAL
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Shervin Pishevar              
	
             

          	
            Name:

          	Shervin Pishevar
	
             

          	
            Title:

          	Managing Director
	 	 	 
	 	Address:

          	382 NE 191st ST #24148

            Miami, FL 33179

    

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	NOW INVESTMENTS, INC.
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Peter Sadek             
	
             

          	
            Name:

          	Peter Sadek
	
             

          	
            Title:

          	Director
	 	 	 
	 	Address:

          	
            Craigmuir Chambers, Road Town 

            VG1110 Tortola, BVI

          

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    

    

    

    

    IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

     

    

     

    

     

    

    	
             

          	
            INVESTORS:

          
	
             

          	
             

          
	
             

          	PPC IP INVESTOR 2020-II LLC
	
             

          	
             

          
	
             

          	
            By:

          	/s/ Ceron Rhee            
	
             

          	
            Name:

          	Ceron Rhee
	
             

          	
            Title:

          	Manager
	 	 	 
	 	Address:

          	11150 Santa Monica Blvd, Suite 1510

            Los Angeles, CA 90025

    

    
      SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

      
        

      

    

    SCHEDULE A

       

       

        Investors

    

    

    Investor

    

    

    Sherpa Ventures Fund, LP

    800 Market Street, Floor 8

    San Francisco, CA 94102

    [***]

    

    

    

    Sherpa Ventures Fund II, LP

    800 Market Street, Suite

    800 San Francisco, CA 94102

    [***]

    

    

    NVGA I, LLC

    c/o Sierra Fiduciary Support Services

    100 West Liberty St., Ste. 750

    Reno, NV 89501

    [***]

    

    

    Johnson & Johnson Innovation – JJDC, Inc.

    410 George Street

    New Brunswick, New Jersey 08901

    Attention:  Vijay Murthy & Linda Vogel

    

    

    With a copy to:

    

    

    Johnson & Johnson Law Department

    Johnson & Johnson

    One Johnson & Johnson Plaza

    New Brunswick, New Jersey 08933

    Attention:  Kevin Norman, Senior Counsel, Equity

    Transactions

    

    

    Cove Investors I, LLC

    865 South Figueroa Street, 7th

    Floor Los Angeles, CA 90017

    

    

    Cove Investors II, LLC

    865 South Figueroa Street, 7th

    Floor Los Angeles, CA 90017

    

    

    Code Holdings LLC

    Attn:  Robert L. Schooler, CFO

    101 Second Street, Suite 2225 San Francisco, CA 94105

    

    

    
      
        

      

    

    RONO, LLC

    145 Reade Street, Apt. 175

    New York, NY 10013

    

    

    Rohan Oza

    [***]
    

    

    WEHO Investments, LLC

    Attn:  Robert P. Hrtica, Manager

    c/o Appian Way

    9255 Sunset Blvd., Suite 615

    West Hollywood, CA 90069

    

    

    Been There, LLC

    Attn:  Kenneth B. Hertz, Managing Member

    1800 Century Park East, Suite 1000

    Los Angeles, CA 90067

    

    

    John C. Kennedy

    [***]
    

    

    The Tanbark Trust

    c/o Lee C. Linden, Trustee

  

   [***]
     

    

    Amber R. Arbucci

    [***]
    

    

    Vincent V. Laresca

    [***]
    

    

    Jason Goldberg

    [***]
    

    

    Charles M. Pacheco

  

  [***]
     

    

    Di-Ann Eisnor

    [***]
    

    

    
      
        

      

    

    Trendtrade International P/L

    Attn:  Lance Kalish, Director

    [***]

    

    

    The Marc R. Benioff Revocable Trust u/a/d 12/3/04

    c/o Marc R. Benioff, Trustee

    [***]
    

    

    Brooklyn Elias

    [***]
    

    

    Mokhtarzada Holdings, LLC

    Attn:  Haroon Mokhtarzada

    [***]
    

    

    April D. Underwood

    [***]
    

    

    James A Messina

    [***]
    

    

    Playtime Ventures, LLC

    Attn:  Mr. John Shahidi

    [***]
    

    

    Sage Spring Partners LLC

    Attn:  Bikram Dang, Partner

  

  [***]
     

    

    Greg Silverman

    [***]
    

    

    
      
        

      

    

    Treeline Interactive, LLC

    3725 Mission Blvd.

    San Diego, CA 92109

    

    

    Flat World (Cue) LP

    386 Park Ave South

    18th Floor

    New York, New York 10013

    

    

    Flat World (Cue III) LP

    3725 Mission Blvd.

    San Diego, CA 92109

    

    

    Neeraj Chandra

  

  [***]
     

    

    RCHI, LLC

    c/o The Yucaipa Companies

    9130 West Sunset Boulevard

    Los Angeles, CA 90069

    Attn:  Legal Department

    [***]
     

    

    Greyscale, LLC

    121 Kercheval Avenue

    Gross Pointe, MI 48236

    

    

    Rajendra Singh 2008 Family Trust

    23 Indian Creek Island Road

    Indian Creek Village, FL 33154

    [***]
     

    

    10100 LLC

    Dept #1178

    PO Box 2652

    Menlo Park, CA 94026

    [***]

    

    

    American Fidelity

    9000 Cameron Parkway

    Oklahoma City, OK 73114

    Attn:  Jim Wheeler

    [***]

    

    

    
      
        

      

    

    Broad Street Principal Investments, L.L.C.

    

    200 West Street

    New York, NY 10282

    Attn:  Benjamin Hohl

    [***]
     

    

    IHS Ventures Partners LLC

    600 Brickell Avenue

    Suite 1725

    Miami, FL 33131

    

    

    Dentsu Ventures Global Fund I

    1-8-1

    Higashi-Shimbashi,

    Minato-Ku, Tokyo

    105-7001, Japan

    

    

    KBBO Ventures

    38th KBBO Office

    Jumeriah Etihad Towers,

    Abu Dhabi

    

    

    Babel SPV I LLC

    441 Burnett Avenue

    San Francisco, California 94131

    

    

    Babel SPV II LLC

    441 Burnett Avenue

    San Francisco, California 94131

    

    

    Babel Fund I LP

    441 Burnett Avenue

    San Francisco, California 94131

    

    

    Zephyr Cove Capital, LLC

    276 Kingsbury Grade, Suite 2000

    P.O. Box 3390

    Stateline, NV 89449-3390

    

    

    Dr. Vishal Mehta

    [***]
    
      
        

      

    

    Kali J. Caldwell

    [***] 

     

    

    Bravetime International Limited

    P.O. Box 957

    Offshore Incorporations Centre

    Road Town, Tortola, British Virgin Islands

    

    

    ANP Hanover Holdings LLC

    111 S Wacker Drive, Suite 4000

    Chicago, IL 60606

    investments@pritzkergroup.com

    

    

    M13 Holding LLC

    215 La Cienega Blvd #200

    Beverly Hills, CA 90211

    

    

    Troy Capital Partners Fund I, LP

    225 Arizona Avenue, Suite 200

    Santa Monica, CA 90401

    

    

    Hlth Wrk LLC

    Attn:  Chris Achar

    [***]

    

    

    Sarrah Hallock

    [***]
    

    

    Brett Thomas

    [***]
    

    

    Section 32 Fund 2, LP

    Address:  171 Main Street, #671

    Los Altos, CA 94022

    Email:  notice@section32.com

    Attn:  Chief Operating Officer

    

    

    Kevin Krenitsky Revocable Trust 2018

    [***]
    
      
        

      

    

    Decheng Capital China Life Sciences USD Fund III, L.P.

    3000 Sand Hill Rd, Bldg 2, Ste 110

    Menlo Park, CA 94025

    

    

    Madrone Opportunity Fund, L.P.

    1149 Chestnut Street

    Suite 200

    Menlo Park, CA 94025

    [***]

    

    

    Weiji Cui and Jin Zhou, Trustees of the Cui Family Revocable Trust

    [***]
     

    

    Foresite Capital Fund V, L.P.

    600 Montgomery St, Ste 4500

    San Francisco, CA 94111

    Attn:  Dennis Ryan

    [***]

    

    

    Foresite Capital Opportunity Fund V,

    L.P. 600 Montgomery St, Ste 4500

    San Francisco, CA 94111

    Attn:  Dennis Ryan

    [***]

    

    

    Foresite Capital Fund IV, L.P.

    600 Montgomery St, Ste 4500

    San Francisco, CA 94111

    Attn:  Dennis Ryan

    [***]

    

    

    Lindamere Drive, LLC

    865 South Figueroa Street, 7th

    Floor Los Angeles, CA 90017

    [***]

    

    

    Tarsadia Foundation

    520 Newport Center Dr., 21st Floor

    Newport Beach, CA 92660

    Attn:  Rishi Reddy

    [***]

    

    

    PGVC 2018 LLC

    111 S Wacker Drive, Suite 4000

    Chicago, IL 60606

    [***]
    
      
        

      

    

    Art99 Investments LLC

    c/o NKSFB

    810 Seventh Ave, Suite 701

    New York, NY 10019

    [***]
     

    

    Sofreh Capital LP

    382 NE 191st Street #24148

    Miami, FL 33179-3899

    [***]
     

    

    PPC IP Investor 2020-II LLC

    11150 Santa Monica Blvd, Suite 1510

    Los Angeles, CA 90025

    [***]Exhibit 4.3

    

    

      THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS.  THESE SECURITIES
        ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.  HOLDERS SHOULD
        BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.  THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN THE FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT
        THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

      

      

      CUE INC.

      

      

      WARRANT TO PURCHASE COMMON STOCK

      

      

      CSW-4

      

      

      This Warrant (this “Warrant”) certifies that as of August 22, 2017 (the “Issue Date”), WEHO Investments LLC (“Holder”) is entitled to subscribe for and purchase, subject to the terms hereof, up to an aggregate of 75,744 shares of Class A Common Stock (the “Warrant Shares”) of Cue,
        Inc., a Delaware corporation (the “Company”), and at a purchase price per share equal to $0.40 (the “Warrant Price”), in each case as adjusted pursuant to Article 3
        hereof.  This Warrant is issued pursuant to the Advisor Agreement, dated of even date herewith (the “Advisor Agreement”), between the Company and the Holder, pursuant to which the Holder is providing services to the Company.  Unless
        otherwise defined herein, capitalized terms shall have the meaning set forth in the Advisor Agreement.

      

      

      Holder (as defined below) shall be only entitled to exercise this Warrant for Vested Warrant Shares in accordance with the terms hereof and during the period commencing on the Initial Vesting Date,
        if any, and ending on the earliest to occur of (i) a Sale of the Company, and (ii) 5:00 p.m. PST on the tenth (10th) anniversary of the Exercise Commencement Date,
        upon the occurrence of which this Warrant shall expire and be cancelled, with no further force or effect.  During the term of this Warrant, the Company shall provide Holder with at least ten (10) days prior written notice of a Sale of the Company. 
        The number of Warrant Shares purchasable upon exercise of this Warrant is subject to vesting as provided in Section 2.8 below.

      

      

      ARTICLE 1.

      DEFINITIONS

      

      

      1.1          “Affiliate” shall mean, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is
        under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital, private equity or other similar fund now or hereafter existing that is controlled
        by one or more general partners or managing members of, or shares the same management company with, such Person.  “Affiliate” shall also mean, in the case of any venture capital, private equity or other similar fund now or hereafter existing that
        is an Investor, all partners, members, shareholders or other equity holders of any kind of such venture capital, private equity or other similar fund, regardless of whether such partners, members, shareholders or other equity owners control such
        venture capital, private equity or other similar fund.

      
        
          

      

      
      1.2          “Aggregate Price” shall mean the total number of Warrant Shares multiplied by the Warrant Price.

      

      

      1.3          “Sale of the Company” means either: (a) a transaction or series of related transactions in which a Person, or a group of related Persons,
        acquires from shareholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a “Stock Sale”); or (b) a transaction that qualifies as a “Liquidation Event” as defined in the Certificate.

      

      

      1.4          “Class A Common Stock” shall mean the Company’s Class A Common stock, no par value.

      

      

      1.5          “Holder” shall have the meaning set forth in the introductory paragraph above, or any party to whom this Warrant is assigned in compliance with
        the terms hereof.

      

      

      1.6          “Person” shall mean any individual, corporation, partnership, trust, limited liability company, association or other entity.

      

      

      1.7          “Securities Act” shall mean the Securities Act of 1933, as amended.

      

      

      1.8          “Vesting Commencement Date” shall mean the Issue Date.

      

      

      ARTICLE 2.

      EXERCISE AND PAYMENT

      

      

      2.1          Cash Exercise.  The purchase rights represented by this Warrant may be exercised by the Holder, in whole or in part, by the
        surrender of this Warrant at the principal office of the Company, located at the address set forth on the signature page hereof, accompanied by the form of Notice of Cash Exercise in substantially the form attached hereto as Exhibit A-1 (the “Notice of Cash Exercise”) and by the payment to the Company, by cash or by certified, cashier’s or other check acceptable to the Company, of an amount
        equal to the aggregate Warrant Price of the Warrant Shares being purchased.

      

      

      2.2          Net Issue Exercise.  In lieu of exercising this Warrant pursuant to Section 2.1, the Holder may elect to receive shares of
        Class A Common Stock equal to, in whole or in part, the value of this Warrant determined in the manner described below (or of any portion thereof remaining unexercised) by surrender of this Warrant at the principal office of the Company together
        with the form of Notice of Cashless Exercise in substantially the form attached hereto as Exhibit A-2 (the “Notice of Cashless Exercise” and together with the Notice
        of Cash Exercise, each a “Notice of Exercise”) in which event the Company shall issue to the Holder a number of shares of the Class A Common Stock computed using the following formula:

      

      

      X = Y (A-B)

      

      

             A

      
        2

        
          

      

      	
              Where

            	
              X  =  the number of Warrant Shares to be issued to the Holder of this Warrant (on the date of such calculation).

               

              Y  =  the number of Warrant Shares purchasable under this Warrant on the date of such calculation (or, if this Warrant is exercised in part, the number of Warrant Shares represented by
                the portion of this Warrant being exercised).

               

              A  =  the fair market value of one share of the Class A Common Stock (on the date of such calculation).

               

              B  =  Warrant Price (as adjusted in accordance with Article 3 as applicable to the date of such calculation).

            

      

      

      

      

      2.3          Fair Market Value.  For purposes of this Article 2, except as set forth in clause (ii) below, the fair market value of one
        share of the Class A Common Stock shall mean as follows:

      

      

      (i)          The per share fair market value of the Class A Common Stock shall be as determined in the reasonable and good faith discretion of the Company’s Board of Directors; and

      

      

      (ii)          Notwithstanding the foregoing, in the event this Warrant is exercised in connection with any Sale of the Company, the fair market value per share of Class A Common Stock shall be the
        price per share paid to the holders of such Class A Common Stock in such Sale of the Company transaction, or if no payment is made to such holders in connection with such Sale of the Company transaction, then the amount per share that would be paid
        to such holders if, immediately after such Sale of the Company transaction the Company (or its successor in interest, as the case may be) were to liquidate and distribute the value of all of its assets to its shareholders after settling its debts.

      

      

      2.4          Stock Certificates.  In the event of any exercise of the rights represented by this Warrant, certificates for the shares of
        Class A Common Stock so purchased shall be delivered to the Holder within a reasonable time and, unless this Warrant has been fully exercised for the Maximum Warrant Shares or has expired, a new Warrant representing the number of shares that can be
        acquired, subject to any remaining vesting conditions, for the remaining unexercised Aggregate Price shall also be issued to the Holder at such time.  Notwithstanding the date of the delivery of the certificate(s) for the Class A Common Stock, the
        person in whose name the certificate(s) for such capital stock are to be issued shall be deemed to have become a stockholder of record on the next succeeding day on which the transfer books are open after the date of the appropriate Notice of
        Exercise is received by the Company.

      

      

      2.5          Stock Fully Paid.  The Company represents and warrants that all Class A Common Stock which may be issued upon the exercise
        of the rights represented by this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, security interests, liens, charges (excluding taxes based on the income of the Holder), except
        to the extent imposed by or as a result of the status, act or omission of, the Holder.

      
        3

        
          

      

      2.6          Fractional Shares.  No fractional share of Class A Common Stock will be issued in connection with any exercise hereof; in
        lieu of a fractional share upon complete exercise hereof, the Holder may purchase a whole share by delivering payment equal to the appropriate portion of the then effective Warrant Price.

      

      

      2.7          Conditional Exercise.  Notwithstanding anything to the contrary herein, any Notice of Exercise may be conditioned, and
        effective only, upon the occurrence of any event(s) specified therein, including the consummation of a Sale of the Company or the declaration of a dividend.

      

      

      2.8          Vesting.  This Warrant shall be exercisable for up to the number of Warrant Shares
        set forth on the cover page of this Warrant (the “Maximum Shares Amount”) based upon the following vesting condition (such Warrant Shares which shall have vested in accordance with the terms hereof, “Vested Warrant Shares”): fifty percent (50%) of the total Warrant Shares subject to this Warrant (i.e., 37,872) shall vest, if at all, on the first anniversary of the Vesting Commencement Date (the “Initial Vesting Date”), and the remaining fifty percent (50%) of the Warrant Shares shall vest in 1/24th increments (i.e., 3,156) of the total number of Warrant Shares granted hereunder shall become Vested
        Warrant Shares on the last day of each full calendar month in each case only if Holder is continuously providing services per the Advisor Agreement through the applicable vesting date.  Notwithstanding the foregoing, vesting of the Warrant Shares
        shall accelerate and this Warrant shall be exercisable for the full Maximum Shares Amount upon (i) a Sale of the Company or (ii) any termination of the Advisor Agreement (x) by Holder due to the Company’s material breach of the Advisor Agreement or
        (y) by the Company for any reason other than an uncured material breach of the Advisor Agreement by Advisor.  Holder may purchase such Vested Warrant Shares at any time on or after the initial number of Vested Warrant Shares have vested.  In lieu
        of any fractional amount of vesting, the Company may elect to pay to Holder an amount of cash equal to such incremental value.

      

      

      ARTICLE 3.

      CERTAIN ADJUSTMENTS OF NUMBER OF

      SHARES PURCHASABLE AND WARRANT PRICE

      

      

      The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the happening of certain events, as
        follows:

      

      

      3.1          Reclassification or Consolidation.  In case of any reclassification or change of outstanding securities issuable upon
        exercise of this Warrant, the Company, shall execute a new warrant of like form, tenor and effect and which will provide that the Holder shall have the right to exercise such new warrant and purchase upon such exercise, in lieu of each share of
        Class A Common Stock theretofore issuable upon exercise of this Warrant, the kind and amount of securities, money and property receivable upon such reclassification, change or consolidation by a holder of one share of Class A Common Stock issuable
        upon exercise of this Warrant had this Warrant been exercised immediately prior to such reclassification, change, or consolidation.  Such new Warrant shall be as nearly equivalent in all substantive respects as practicable to this Warrant and the
        adjustments provided in this Article 3 and the provisions of this Section 3.1, shall similarly apply to successive reclassifications, changes, and consolidations.

      
        4

        
          

      

      3.2          Subdivision or Combination of Shares.  If the Company shall at any time while this Warrant remains outstanding and less than
        fully exercised: (i) split or subdivide its Class A Common Stock, the Warrant Price shall be proportionately reduced; or (ii) shall combine or reverse-split shares of its Class A Common Stock, the Warrant Price shall be proportionately increased.

      

      

      3.3          Time of Adjustments to the Warrant Price and Shares Purchasable.  All adjustments to the Warrant Price and the number of
        shares purchasable hereunder, unless otherwise specified herein, shall be effective, as applicable, as of the earliest of:

      

      

      (i)          the date of issue of the security, or the occurrence of the other event, causing the adjustment;

      

      

      (ii)          the date of sale of the security causing the adjustment;

      

      

      (iii)          the effective date of a division or combination of shares; and

      

      

      (iv)          the record date of any action of holders of any class of the Company’s capital stock taken for the purpose of entitling the stockholders of the Company to receive a distribution or
        dividend payable in equity securities, provided that such division, combination, distribution or dividend actually occurs;

      

      

      provided, however, that notwithstanding anything else to the contrary herein, the first adjustment, if applicable, to the Warrant Price and the number of shares purchasable
        hereunder, shall be calculated based off of the initial aggregate number of Warrant Shares hereunder.

      

      

      3.4          Notices.  During the term of this Warrant, in addition to any other notices required or permitted hereunder, at least
        fourteen (14) days prior to (i) the Company declaring a record date for holders of its Class A Common Stock (or any other securities receivable upon the exercise of this Warrant) for the purpose of entitling such holders to receive any dividend,
        distribution, right to subscribe or purchase other securities or any other right; (ii) any reclassification or change of outstanding securities issuable upon exercise of this Warrant; (iii) any Sale of the Company or any consolidation or merger of
        the Company with or into another corporation (other than a merger with another corporation in which the Company is a continuing corporation and which does not result in any reclassification, change or exchange of outstanding securities issuable
        upon exercise of this Warrant); (iv) any sale or transfer to another corporation or entity of all, or substantially all, of the property of the Company; (v) any voluntary dissolution, liquidation or winding-up of the Company; or (vi) any public
        offering of the Company’s capital stock pursuant to an effective registration statement under the Securities Act, the Company shall give notice to the Holder stating the record date for determining the holders entitled to such distribution or the
        date on which securities of the Company are to be exchanged in connection with a reclassification, consolidation, merger, sale of all or substantially all the assets of the Company, dissolution, liquidation or winding-up is to take place and the
        date, if any, on which the capital stock of the Company is to be exchanged in connection therewith.

      
        5

        
          

      

      3.5          Duration of Adjusted Warrant Price.  Following each adjustment of the Warrant Price, such adjusted Warrant Price shall
        remain in effect until a further adjustment of the Warrant Price.

      

      

      3.6          Adjustment of Number of Shares.  Upon each adjustment of the Warrant Price pursuant to this Article 3, the number of shares
        of Class A Common Stock purchasable hereunder shall be adjusted to the nearest whole share, to the number obtained by dividing the Aggregate Price by the Warrant Price as adjusted.

      

      

      ARTICLE 4.

      TRANSFER, RIGHT OF FIRST REFUSAL; DRAG ALONG; EXCHANGE AND LOSS

      

      

      4.1          Transfer.  This Warrant and any and all rights hereunder are not transferable unless otherwise agreed to by Company in
        writing, which agreement may be withheld in the Company’s sole and absolute discretion.  The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions.

      

      

      4.2          Right of First Refusal.  The shares of Class A Common Stock issuable upon exercise of this Warrant are subject to a right of
        first refusal as set forth in the Company’s Bylaws (the “ROFR”).  Before any such shares of Class A Common Stock issuable upon exercise of this Warrant (or any beneficial interest in such shares) may be sold,
        transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by Holder or any subsequent transferee, such party must first offer such shares or beneficial interest to the Company and/or its assignee(s) in
        accordance with the terms of the ROFR.

      

      

      4.3          Drag Along.  In the event that (i) the Board, (ii) the holders of the majority of the shares of Common Stock then issued or
        issuable upon conversion of the shares of the Company’s Preferred Stock (the “Selling Investors”); and (iii) the holders of the majority of the shares of Common Stock then issued and outstanding (other than
        those issued or issuable upon conversion of the Preferred Stock) (collectively, the “Electing Holders”), approve a Sale of the Company, then Holder agrees (such agreement the Company’s “Drag-Along Right”) with respect to all shares of capital stock of the Company pursuant to this Warrant that it holds or otherwise exercises dispositive power as follows:

      

      

      (i)             in the event such transaction requires the approval of the stockholders of the Company, (x) if the matter is to be brought to a vote at a stockholder meeting, after receiving proper
        notice of any meeting of stockholders of the Company to vote on the approval of a Sale of the Company, to be present, in person or by proxy, as a holder of shares of capital stock, at all such meetings and be counted for the purposes of determining
        the presence of a quorum at such meetings; and (y) to vote (in person, by proxy or by action by written consent, as applicable) all shares of capital stock in favor of such Sale of the Company and in opposition of any and all other proposals that
        could reasonably be expected to delay or impair the ability of the Company to consummate such Sale of the Company;

      
        6

        
          

      

      (ii)          in the event that the Sale of the Company is to be effected by the sale of shares of capital stock by the Company’s stockholders (the “Selling Holders”) without the need for
        stockholder approval, Holder agrees to sell all shares of capital stock that it beneficially holds (or in the event that the Selling Holders are selling fewer than all of their shares of capital stock of the Company, shares in the same proportion
        as the Selling Holders are selling) to the person to whom the Selling Holders propose to sell their shares of capital stock;

      

      

      (iii)          to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time with respect to such Sale of the Company;

      

      

      (iv)          to execute and deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably be requested by the Company;

      

      

      (v)           in the event that the Electing Holders, in connection with such Sale of the Company, appoint a stockholder representative (the “Stockholder Representative”) with respect to
        matters affecting the stockholders of the Company under the applicable definitive transaction agreements following consummation of such Sale of the Company, (x) to consent to (i) the appointment of such Stockholder Representative, (ii) the
        establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of Holder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and
        all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s services and duties in connection with such Sale of the Company and its related service as the representative of the
        stockholders of the Company, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other stockholder of the Company with respect to any action or inaction taken or failed to be taken by the Stockholder
        Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct;

      

      

      (vi)          if the consideration to be paid in exchange for the shares pursuant such Sale of the Company includes any securities and due receipt thereof by Holder would require under applicable
        law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities or (y) the provision to Holder of any information other than such information as a prudent issuer would
        generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company may cause to be paid to Holder in lieu thereof, against surrender of the shares
        which would have otherwise been sold by Holder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which Holder would otherwise receive as of the date of the issuance of such securities in
        exchange for such shares; and

      

      

      (vii)          not to deposit any voting securities owned by Holder in a voting trust or subject any such voting securities to any arrangement or agreement with respect to the voting of such shares
        of capital stock, unless specifically requested to do so by the acquiror in connection with a Sale of the Company.

      
        7

        
          

      

      Notwithstanding the foregoing, Holder will not be required to comply with these restrictions in connection with any proposed Sale of the Company unless (1) Holder receives with respect to Holder’s shares of a class
        or series of capital stock consideration per share that is no less than every other stockholder participating in the Sale of the Company with respect to his, her or its shares of the same class or series of capital stock, (2) the proceeds payable
        to Holder in connection with such transaction are equal to or greater than the proceeds required to be paid to Holder pursuant to the Company’s certificate of incorporation in effect at such time, (3) Holder’s maximum liability in connection with
        such Sale of the Company does not exceed the consideration payable to Holder in such Sale of the Company (other than in the case of potential liability for fraud or willful misconduct or breach of a representation by Holder relating to Holder’s
        title to Holder’s securities as to which liability there need not be any such limitation) and (4) the terms of such transaction applicable to Holder are materially no less favorable than the terms applicable to each other stockholder holding the
        same class or series of shares as Holder.

      

      

      By Holder’s execution of this Warrant, Holder hereby constitutes and appoints the President and Secretary of the Company, and each of them, with full power of substitution, as Holder’s proxies with respect to the
        Drag- Along Right, including without limitation, votes regarding any Sale of the Company, and hereby authorize each of them to represent and to vote, if and only if Holder (i) fails to vote or (ii) attempts to vote (whether by proxy, in person or
        by written consent), in a manner that is inconsistent with the terms of this Warrant, all of Holder’s shares of capital stock of the Company in favor of any Sale of the Company pursuant to and in accordance with the terms and provisions hereof. 
        The proxy granted pursuant to the immediately preceding sentence is given for good and valuable consideration the receipt and sufficiency is hereby acknowledged and, as such, is coupled with an interest and shall be irrevocable unless and until
        this Warrant terminates or expires.

      

      

      4.4          Securities Laws.  In connection with the issuance of shares of Class A Common Stock to the Holder, the Holder agrees to
        execute an investment intent letter or purchase agreement in such form as reasonably requested by the Company and its counsel and as may be required to comply with federal and applicable state securities laws.  If required by the Company, in
        connection with each issuance of shares of Class A Common Stock upon exercise of this Warrant, the Holder will give: (i) assurances in writing, satisfactory to the Company’s counsel, that such shares are not being purchased with a view to the
        distribution thereof in violation of applicable laws, (ii) sufficient information, in writing, to enable the Company’s counsel to reasonably rely on exemptions from the registration or qualification requirements of applicable laws, if available,
        with respect to such exercise, and (iii) its cooperation to the Company in connection with such compliance.

      

      

      4.5          Exchange.  This Warrant is exchangeable at the principal office of the Company for Warrants which represent, in the
        aggregate, the applicable Aggregate Price and aggregate number of Vested Warrant Shares hereunder; each new Warrant to represent the right to purchase such portion of the Aggregate Price and aggregate number of Warrant Shares, whether or not
        vested, hereunder as the Holder shall designate at the time of such exchange.  Each new Warrant shall be identical in form and content to this Warrant, except for appropriate changes in the number of shares of Class A Common Stock covered thereby,
        the percentage stated in Section 4.1 above, and any other changes which are necessary in order to prevent the Warrant exchange from changing the respective rights and obligations of the Company and the Holder as they existed immediately prior to
        such exchange.

      
        8

        
          

      

      4.6          Loss or Mutilation.  Upon receipt by the Company of evidence satisfactory to it of the ownership of, and the loss, theft,
        destruction or mutilation of, this Warrant and in the case of loss, theft, or destruction, of indemnity satisfactory to it, and in the case of mutilation, upon surrender and cancellation hereof, the Company will execute and deliver in lieu hereof a
        new Warrant identical in form and content.

      

      

      ARTICLE 5.

      HOLDER RIGHTS

      

      

      5.1          No Stockholder Rights Until Exercise.  The Holder, solely by virtue of the existence of this Warrant, shall not be entitled
        to any rights as a stockholder of the Company until this Warrant is exercised for Warrant Shares in accordance with the terms hereof.

      

      

      5.2          Restrictions on Transfer of Shares of Class A Common Stock.  Holder acknowledges and understands that the shares of Class A
        Common Stock issuable upon exercise hereof are subject to certain restrictions on transfer, including, without limitation, a right of first refusal and market standoff provision, as set forth in the Company’s Bylaws.

      

      

      ARTICLE 6.

      REPRESENTATIONS AND WARRANTIES BY THE HOLDER

      

      

      The Holder represents and warrants to the Company as follows:

      

      

      6.1          This Warrant and the Class A Common Stock issuable upon exercise hereof are being acquired for its own account, for investment and not with a view to, or for resale in connection with,
        any distribution or public offering thereof within the meaning of the Securities Act.  Upon exercise of this Warrant, the Holder shall, if so requested by the Company, confirm in writing, in a form satisfactory to the Company’s counsel, that the
        securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale in violation of applicable securities laws.

      

      

      6.2          The Holder understands that the Warrant and the Class A Common Stock issuable hereunder have not been registered under the Securities Act by reason of their issuance in a transaction
        exempt from the registration and prospectus delivery requirements of the Securities Act pursuant to Section 4(a)(2) thereof, and that they must be held by the Holder indefinitely, and that the Holder must therefore bear the economic risk of such
        investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempted from such registration.

      

      

      6.3          The Holder understands that no federal or state securities administrator has made any finding or determination relating to the fairness of investment in the Company or purchase of the
        Class A Common Stock hereunder and that no federal or state securities administrator has recommended or endorsed the offering of securities by the Company hereunder.

      
        9

        
          

      

      6.4          The Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of this Warrant and the Class A
        Common Stock purchasable pursuant to the terms of this Warrant and of protecting its interests in connection therewith.

      

      

      6.5          The Holder is able to bear the economic risk of the purchase of the Class A Common Stock pursuant to the terms of this Warrant.

      

      

      6.6          Holder has reviewed with Holder’s own tax advisors the federal, state, local and foreign tax consequences of the transactions contemplated by this Warrant.  Holder is relying solely on
        such advisors and not on any statements or representations of the Company or any of its agents.  Holder understands that Holder (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions
        contemplated by this Warrant.

      

      

      6.7          The Holder is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

      

      

      ARTICLE 7.

      MISCELLANEOUS

      

      

      7.1          GOVERNING LAWS.  IT IS THE INTENTION OF THE PARTIES HERETO THAT THE INTERNAL LAWS OF THE STATE OF CALIFORNIA (IRRESPECTIVE
        OF ITS CHOICE OF LAW PRINCIPLES) SHALL GOVERN THE VALIDITY OF THIS WARRANT, THE CONSTRUCTION OF ITS TERMS, AND THE INTERPRETATION AND ENFORCEMENT OF THE RIGHTS AND DUTIES OF THE PARTIES HERETO.

      

      

      7.2          Binding Upon Successors and Assigns.  Subject to, and unless otherwise provided in, this Warrant, each and all of the
        covenants, terms, provisions, and agreements contained herein shall be binding upon, and inure to the benefit of the permitted successors, executors, heirs, representatives, administrators and assigns of the parties hereto.

      

      

      7.3          Severability.  If any one or more provisions of this Warrant, or the application thereof, shall for any reason and to any
        extent be invalid or unenforceable, the remainder of this Warrant and the application of such provisions to other persons or circumstances shall be interpreted so as best to reasonably effect the intent of the parties hereto.  The parties further
        agree to replace any such void or unenforceable provisions of this Warrant with valid and enforceable provisions which will achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provisions.

      

      

      7.4          Default, Amendment and Waivers.  Any provision of this Warrant may be amended, waived or modified upon the written consent
        of the Company and the Holder.  The failure of any party to enforce any of the provisions hereof shall not be construed to be a waiver of the right of such party thereafter to enforce such provisions.  The waiver by a party of any breach hereof for
        default in payment of any amount due hereunder or default in the performance hereof shall not be deemed to constitute a waiver of any other default or any succeeding breach or default.  The failure to cure any breach of any term of this Warrant
        within ten (10) days of written notice thereof shall constitute an event of default under this Warrant.

      
        10

        
          

      

      7.5          Notices.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
        deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal
        business hours, then on the recipient’s next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day after deposit with a nationally
        recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt.  All communications shall be sent to the respective parties at their address as set forth on the signature page, or to such
        e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 7.5.  If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Foley &
        Lardner, LLP, 975 Page Mill Road, Palo Alto, CA 94304, Attention: E. Thom Rumberger, Jr..  Any party may change its address for such communications by giving notice thereof to the other party in conformity with this Section 7.5.

      

      

      7.6          Construction of Agreement.  A reference in this Warrant to any section shall include a reference to every section the number
        of which begins with the number of the Section to which reference is specifically made (e.g., a reference to Section 3 shall include a reference to Sections 3.4 and 3.6).  The titles and headings herein are for reference purposes only and shall not
        in any manner affect the interpretation of this Warrant.  All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine or neuter, singular or plural, as the identity of the person, persons, entity or entities may
        require.

      

      

      7.7          Full Payment.  Holder hereby acknowledges and agrees that the issuance of this Warrant represents the sole obligation of the
        Company and its affiliates to Holder for all services rendered to the Company by Holder pursuant to the Advisor Agreement.

      

      

      7.8          Further Assurances.  Each party agrees to cooperate fully with the other parties and to execute such further instruments,
        documents and agreements and to give such further written assurances, as may be reasonably requested by any other party to better evidence and reflect the transactions described herein and contemplated hereby, and to carry into effect the intents
        and purposes of this Warrant.

      

      

      7.9          Restricted Shares.  The shares of Class A Common Stock purchasable under this Warrant are subject to restrictions on
        transfer and shall not be sold or transferred unless either (i) they first shall have been registered under the Securities Act, or (ii) the Company first shall have been furnished with evidence, which may be an opinion of legal counsel,
        satisfactory to the Company’s counsel to the effect that such sale or transfer is exempt from the registration requirements of the Securities Act, and the other requirements of Sections 4.1 through 4.4 inclusive hereof have been satisfied, as
        applicable.

      

      

      7.10          Counterparts.  This Warrant may be executed in two or more counterparts, each of which shall be deemed an original, but all
        of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
        validly delivered and be valid and effective for all purposes.

      

      

      [Signature Page Follows]

      
        11

        
          

      

      

      

      IN WITNESS WHEREOF, the parties hereto have executed this Warrant on the date first written above.

      

      

      
        	
                 

              	COMPANY:
	
                 

              	
                 

              	
                 

              
	
                 

              	CUE, INC.
	
                 

              	
                 

              	
                 

              
	
                 

              	By: 

              	 /s/ Ayub Khattak
	
                 

              	Name:	
                Ayub Khattak

              
	
                 

              	Title:	Chief Executive Officer
	
                 

              	
                 

              	
                 

              
	 	Address: 	11100 Roselle St. Suite A
	 	 	
                San Diego, CA 92121

              
	 	Email:	[***]

      

      

      

      Agreed and Acknowledged:

      

      

      HOLDER:

      

      

      WEHO INVESTMENTS, LLC

       

      

      
        	By: 

              	 /s/ Robert P. Hrtica	
                 

              
	Name:	Robert P. Hrtica	
                 

              
	Title:	 Manager	
                 

              
	
                 

              	
                 

              	
                 

              
	Address:   

              	
                9255 W. Sunset Blvd., Ste. 615

                West Hollywood, CA 90069 

              	
                 

              

      

          

      

      

      

      [Signature Page to Cue Inc. Common Stock Warrant]

      
        
          

      

      
      EXHIBIT “A-1”

      

      

      FORM NOTICE OF EXERCISE OF WARRANT BY CASH PAYMENT OF WARRANT PRICE

      

      

      [insert date]

       

      

      Cue, Inc.

      11100 Roselle St. Suite A

      San Diego, CA 92121

      Attention: Chief Executive Officer

      

      

      CASH EXERCISE

      

      

      Ladies and Gentlemen:

      

      

      The undersigned registered Holder of the Warrant to Purchase Stock delivered herewith (“Warrant”), hereby irrevocably exercises such Warrant for, and purchases thereunder, shares of the Class A
        Common Stock (the “Common Stock”) of Cue Inc., a Delaware corporation (the “Company”), as provided below.  Capitalized terms used herein, unless otherwise defined herein, shall have the meanings given in the Warrant.  The portion of the Aggregate
        Price (as defined in the Warrant) to be applied toward the purchase of Common Stock pursuant to this Notice of Exercise is $     , thereby leaving a remainder Aggregate Price (if any) equal to $     .  Such exercise shall be pursuant to the cash
        exercise provisions of Section 2.1 of the Warrant.  Therefore, the Holder makes payment with this Notice of Exercise by way of [check payable or wire transfer (cross out inapplicable payment method)] to the Company in the amount of $    .  Such
        [check or wire transfer (cross out inapplicable payment method)] is payment in full under the Warrant for shares of Common Stock based upon the Warrant Price of $per share, as currently in effect under the Warrant.  The Holder requests that the
        certificates for the purchased shares of Common Stock be issued in the name of and delivered to.  To the extent the foregoing exercise is for less than the full Aggregate Price, a replacement Warrant representing the remainder of the Aggregate
        Price and otherwise of like form, tenor and effect should be delivered to the Holder along with the share certificates evidencing the Common Stock issued in response to this Notice of Exercise.

      

      

      The undersigned represents that the aforesaid shares of Common Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with,
        the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares except in compliance with applicable securities laws and all representations and warranties of the undersigned set forth in Section
        6 of the attached Warrant are true and correct as of the date hereof.  Additionally, the undersigned agrees and covenants to abide by the transfer restriction terms and conditions as set forth in Sections 4.1 through 4.6, inclusive, of the Warrant,
        as well as the restrictions on transfer imposed on the shares of Common Stock pursuant to the Company’s Amended and Restated Bylaws, as amended.

      
        A1-1

        
          

      

       
        	
                 

              	HOLDER
	
                 

              	
                 

              	
                 

              
	
                 

              	By:	
                 

              
	
                 

              	Name:	
                 

              
	
                 

              	Title:	
                 

              

      

       

        

      NOTE: The signature to the foregoing Notice of Exercise must exactly correspond to the name of the Holder as typed on Warrant.

      
        A1-2

        
          

      

      
      EXHIBIT “A-2”

       

      

      FORM OF NOTICE OF EXERCISE OF WARRANT PURSUANT TO NET ISSUE

      (“CASHLESS”) EXERCISE PROVISIONS

      

      

      [insert date]

      

      

      Cue, Inc.

      11100 Roselle St. Suite A

      San Diego, CA 92121

      Attention: Chief Executive Officer

      

      

      CASHLESS EXERCISE

      

      

      Ladies and Gentlemen:

      

      

      The undersigned, registered Holder of the Warrant to Purchase Stock delivered herewith (“Warrant”), hereby irrevocably exercises such Warrant for, and purchases thereunder, shares of the Class A Common Stock (the
        “Common Stock”) of Cue Inc., a Delaware corporation (the “Company”), as provided below.  Capitalized terms used herein, unless otherwise defined herein, shall have the meanings given in the Warrant.  The portion of the Aggregate Price (as defined
        in the Warrant) to be applied toward the purchase of Common Stock pursuant to this Notice of Exercise is $     , thereby leaving a remainder Aggregate Price (if any) equal to $     .  Such exercise shall be pursuant to the net issue exercise
        provisions of Section 2.2 of the Warrant; therefore, Holder makes no payment with this Notice of Exercise.  The number of shares to be issued pursuant to this exercise shall be determined by reference to the formula in Section 2.2 of the Warrant
        which, by reference to Section 2.3, requires the use of the current per share fair market value of the Common Stock.  The current fair market value of one share of the Company’s Common Stock shall be determined in the manner provided in Section
        2.3, which amount has been determined or agreed to by Holder and the Company to be $     , which figure is acceptable to Holder for calculations of the number of shares of Common Stock issuable pursuant to this Notice of Exercise, resulting in the
        issuance ofshares of Common Stock.  Holder requests that the certificates for the purchased shares of Common Stock be issued in the name of and delivered to.  To the extent the foregoing exercise is for less than the full Aggregate Price of the
        Warrant, a replacement Warrant representing the remainder of the Aggregate Price (and otherwise of like form, tenor and effect) shall be delivered to Holder along with the share certificate evidencing the Common Stock issued in response to this
        Notice of Exercise.

      

      

      The undersigned represents that the aforesaid shares of Common Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution
        thereof and that the undersigned has no present intention of distributing or reselling such shares except in compliance with applicable securities laws and all representations and warranties of the undersigned set forth in Section 6 of the attached
        Warrant are true and correct as of the date hereof.  Additionally, the undersigned agrees and covenants to abide by the transfer restriction terms and conditions as set forth in Sections 4.1 through 4.6, inclusive, of the Warrant, as well as the
        restrictions on transfer imposed on the shares of Common Stock pursuant to the Company’s Amended and Restated Bylaws, as amended.

      
        A2-1

        
          

      

      

      
        	
                 

              	HOLDER
	
                 

              	
                 

              	
                 

              
	
                 

              	By:	
                 

              
	
                 

              	Name:	
                 

              
	
                 

              	Title:	
                 

              

      

       

        

      NOTE: The signature to the foregoing Notice of Exercise must exactly correspond to the name of the Holder as typed on Warrant.

      

      

    

  

  A2-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]